FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CTPS2-AKAP8

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CTPS2-AKAP8
FusionPDB ID: 20415
FusionGDB2.0 ID: 20415
HgeneTgene
Gene symbol

CTPS2

AKAP8

Gene ID

56474

10270

Gene nameCTP synthase 2A-kinase anchoring protein 8
Synonyms-AKAP 95|AKAP-8|AKAP-95|AKAP95
Cytomap

Xp22.2

19p13.12

Type of geneprotein-codingprotein-coding
DescriptionCTP synthase 2CTP synthase IICTP synthetase type 2UTP-ammonia ligase 2cytidine 5'-triphosphate synthetase 2A-kinase anchor protein 8A kinase (PRKA) anchor protein 8A-kinase anchor protein, 95kDa
Modification date2020031320200313
UniProtAcc

Q9NRF8

Main function of 5'-partner protein: FUNCTION: Catalyzes the ATP-dependent amination of UTP to CTP with either L-glutamine or ammonia as the source of nitrogen. Constitutes the rate-limiting enzyme in the synthesis of cytosine nucleotides. {ECO:0000269|PubMed:10899599, ECO:0000269|PubMed:16179339}.

Q9ULX6

Main function of 5'-partner protein: FUNCTION: Could play a role in constitutive transport element (CTE)-mediated gene expression by association with DHX9. Increases CTE-dependent nuclear unspliced mRNA export (PubMed:10748171, PubMed:11402034). Proposed to target PRKACA to the nucleus but does not seem to be implicated in the binding of regulatory subunit II of PKA (PubMed:10761695, PubMed:11884601). May be involved in nuclear envelope breakdown and chromatin condensation. May be involved in anchoring nuclear membranes to chromatin in interphase and in releasing membranes from chromating at mitosis (PubMed:11034899). May regulate the initiation phase of DNA replication when associated with TMPO isoform Beta (PubMed:12538639). Required for cell cycle G2/M transition and histone deacetylation during mitosis. In mitotic cells recruits HDAC3 to the vicinity of chromatin leading to deacetylation and subsequent phosphorylation at 'Ser-10' of histone H3; in this function seems to act redundantly with AKAP8 (PubMed:16980585). May be involved in regulation of pre-mRNA splicing (PubMed:17594903). {ECO:0000269|PubMed:10748171, ECO:0000269|PubMed:11034899, ECO:0000269|PubMed:11402034, ECO:0000269|PubMed:11884601, ECO:0000269|PubMed:12538639, ECO:0000269|PubMed:16980585, ECO:0000305|PubMed:10761695}.; FUNCTION: (Microbial infection) In case of EBV infection, may target PRKACA to EBNA-LP-containing nuclear sites to modulate transcription from specific promoters. {ECO:0000269|PubMed:11884601}.; FUNCTION: (Microbial infection) Can synergize with DHX9 to activate the CTE-mediated gene expression of type D retroviruses. {ECO:0000269|PubMed:11402034}.; FUNCTION: (Microbial infection) In case of HIV-1 infection, involved in the DHX9-promoted annealing of host tRNA(Lys3) to viral genomic RNA as a primer in reverse transcription; in vitro negatively regulates DHX9 annealing activity. {ECO:0000269|PubMed:25034436}.
Ensembl transtripts involved in fusion geneENST idsENST00000359276, ENST00000380241, 
ENST00000443824, ENST00000483053, 
ENST00000269701, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score8 X 8 X 6=3844 X 5 X 4=80
# samples 117
** MAII scorelog2(11/384*10)=-1.8036027871965
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(7/80*10)=-0.192645077942396
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CTPS2 [Title/Abstract] AND AKAP8 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CTPS2 [Title/Abstract] AND AKAP8 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CTPS2(16711263)-AKAP8(15480990), # samples:2
Anticipated loss of major functional domain due to fusion event.CTPS2-AKAP8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CTPS2-AKAP8 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CTPS2-AKAP8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CTPS2-AKAP8 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID


check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chrX:16711263/chr19:15480990)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CTPS2 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across AKAP8 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000443824CTPS2chrX16711263-ENST00000269701AKAP8chr1915480990-395413837382423561
ENST00000359276CTPS2chrX16711263-ENST00000269701AKAP8chr1915480990-35679963512036561
ENST00000380241CTPS2chrX16711263-ENST00000269701AKAP8chr1915480990-34648931161933605

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000443824ENST00000269701CTPS2chrX16711263-AKAP8chr1915480990-0.0005318530.99946815
ENST00000359276ENST00000269701CTPS2chrX16711263-AKAP8chr1915480990-0.0005969470.999403
ENST00000380241ENST00000269701CTPS2chrX16711263-AKAP8chr1915480990-0.0005728820.9994272

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CTPS2-AKAP8

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CTPS2chrX16711263AKAP8chr19154809901383205EQKTKPTQNSVRALRGLGLSPDLEDE
CTPS2chrX16711263AKAP8chr1915480990893249EQKTKPTQNSVRALRGLGLSPDLEDE
CTPS2chrX16711263AKAP8chr1915480990996205EQKTKPTQNSVRALRGLGLSPDLEDE

Top

Potential FusionNeoAntigen Information of CTPS2-AKAP8 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CTPS2-AKAP8_16711263_15480990.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B48:01TQNSVRAL0.99780.5339614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B39:13TQNSVRAL0.93670.8148614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:05VRALRGLGL0.99840.8451019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:04VRALRGLGL0.99830.80821019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:07VRALRGLGL0.9980.69891019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A74:03TQNSVRALR0.98610.6788615
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A74:11TQNSVRALR0.98610.6788615
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A74:09TQNSVRALR0.98610.6788615
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B14:02VRALRGLGL0.98460.86271019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B14:01VRALRGLGL0.98460.86271019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A31:02TQNSVRALR0.96320.6461615
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B39:24VRALRGLGL0.95440.70921019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B07:10VRALRGLGL0.04960.63891019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B35:03KPTQNSVRAL0.64350.6772414
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B15:04TQNSVRAL0.99150.7473614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B14:03TQNSVRAL0.95090.7644614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A31:01TQNSVRALR0.98680.6103615
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:95VRALRGLGL0.98540.64651019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:05VRALRGLGL0.98070.95821019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:27VRALRGLGL0.95950.94191019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:29VRALRGLGL0.92940.90191019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B39:12VRALRGLGL0.91190.87341019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:13VRALRGLGL0.88870.92641019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:46VRALRGLGL0.81280.88341019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:19VRALRGLGL0.81230.77581019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B14:03VRALRGLGL0.54960.85371019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C12:16VRALRGLGL0.0250.95711019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B39:10KPTQNSVRAL0.62340.7804414
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A31:01KPTQNSVRALR0.98660.7524415
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B39:02TQNSVRAL0.99250.8186614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B15:73TQNSVRAL0.97710.8765614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B15:30TQNSVRAL0.97610.9166614
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:08VRALRGLGL0.99840.74971019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:10VRALRGLGL0.99830.90231019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:06VRALRGLGL0.9980.82411019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B27:09VRALRGLGL0.99790.82411019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:01VRALRGLGL0.98730.64681019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-A74:01TQNSVRALR0.98610.6788615
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C06:08VRALRGLGL0.95720.97971019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B39:31VRALRGLGL0.84950.86931019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:22VRALRGLGL0.73120.67321019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C07:04VRALRGLGL0.64280.87561019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C06:06VRALRGLGL0.36560.991019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C06:17VRALRGLGL0.08250.98541019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-C06:02VRALRGLGL0.08250.98541019
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B35:13KPTQNSVRAL0.63790.6822414
CTPS2-AKAP8chrX16711263chr1915480990996HLA-B67:01KPTQNSVRAL0.5720.6808414

Top

Potential FusionNeoAntigen Information of CTPS2-AKAP8 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CTPS2-AKAP8_16711263_15480990.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0101QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0101TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0101NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0102QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0102TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0102NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0102PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0103QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0103TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0103NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0105QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0105TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0105NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0107QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0107TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0107NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0109QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0109TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0109NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0111QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0111TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0111NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0113QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0113TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0115QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0115TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0115NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0117QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0117TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0117NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0119QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0119TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0119NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0121QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0121TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0123QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0123TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0123NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0123PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0125QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0125TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0125NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0127QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0127TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0127NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0129QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0129TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0129NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0131QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0131TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-0131NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1201QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1201TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1203QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1203TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1204QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1205QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1205TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1206QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1206TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1207QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1207TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1208QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1208TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1208NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1208PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1209QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1210QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1210TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1211QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1211TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1212QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1212TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1213QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1213TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1213NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1213PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1214QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1214TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1215QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1215TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1215NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1215PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1216QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1216TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1217QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1217TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1218QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1218TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1218NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1218PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1219QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1219TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1220QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1220TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1220NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1221QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1221TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1221NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1221PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1222QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1222TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1223QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1223TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1223NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1223PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1504QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1504TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1505QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1507QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1510QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1510TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1521QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1521TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1523QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1527QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1534QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1535QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1537QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1548QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1549QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1601QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1601TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1602QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1603QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1603TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1604QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1604TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1605QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1607QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1608QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1608TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1609QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1610QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1611QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1612QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1614QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1615QNSVRALRGLGLSPD722
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1615TQNSVRALRGLGLSP621
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1615NSVRALRGLGLSPDL823
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1615PTQNSVRALRGLGLS520
CTPS2-AKAP8chrX16711263chr1915480990996DRB1-1616QNSVRALRGLGLSPD722

Top

Fusion breakpoint peptide structures of CTPS2-AKAP8

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
9574TQNSVRALRGLGLSCTPS2AKAP8chrX16711263chr1915480990996

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CTPS2-AKAP8

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN9574TQNSVRALRGLGLS-7.9962-8.1096
HLA-B14:023BVN9574TQNSVRALRGLGLS-5.70842-6.74372
HLA-B52:013W399574TQNSVRALRGLGLS-6.83737-6.95077
HLA-B52:013W399574TQNSVRALRGLGLS-4.4836-5.5189
HLA-A11:014UQ29574TQNSVRALRGLGLS-10.0067-10.1201
HLA-A11:014UQ29574TQNSVRALRGLGLS-9.03915-10.0745
HLA-A24:025HGA9574TQNSVRALRGLGLS-6.56204-6.67544
HLA-A24:025HGA9574TQNSVRALRGLGLS-5.42271-6.45801
HLA-B44:053DX89574TQNSVRALRGLGLS-7.85648-8.89178
HLA-B44:053DX89574TQNSVRALRGLGLS-5.3978-5.5112
HLA-A02:016TDR9574TQNSVRALRGLGLS-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CTPS2-AKAP8

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CTPS2-AKAP8chrX16711263chr19154809901019VRALRGLGLCCAGATCTGGAGGATGAACTCTGCGAC
CTPS2-AKAP8chrX16711263chr1915480990414KPTQNSVRALAGGGGTTTAGGCCTGTCTCCAGATCTGGAG
CTPS2-AKAP8chrX16711263chr1915480990415KPTQNSVRALRAGGGGTTTAGGCCTGTCTCCAGATCTGGAGGAT
CTPS2-AKAP8chrX16711263chr1915480990614TQNSVRALTTAGGCCTGTCTCCAGATCTGGAG
CTPS2-AKAP8chrX16711263chr1915480990615TQNSVRALRTTAGGCCTGTCTCCAGATCTGGAGGAT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CTPS2-AKAP8chrX16711263chr1915480990520PTQNSVRALRGLGLSGGTTTAGGCCTGTCTCCAGATCTGGAGGATGAACTCTGCGACTCT
CTPS2-AKAP8chrX16711263chr1915480990621TQNSVRALRGLGLSPTTAGGCCTGTCTCCAGATCTGGAGGATGAACTCTGCGACTCTGGG
CTPS2-AKAP8chrX16711263chr1915480990722QNSVRALRGLGLSPDGGCCTGTCTCCAGATCTGGAGGATGAACTCTGCGACTCTGGGAGG
CTPS2-AKAP8chrX16711263chr1915480990823NSVRALRGLGLSPDLCTGTCTCCAGATCTGGAGGATGAACTCTGCGACTCTGGGAGGCAA

Top

Information of the samples that have these potential fusion neoantigens of CTPS2-AKAP8

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
ESCACTPS2-AKAP8chrX16711263ENST00000359276chr1915480990ENST00000269701TCGA-LN-A7HY

Top

Potential target of CAR-T therapy development for CTPS2-AKAP8

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CTPS2-AKAP8

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CTPS2-AKAP8

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource